Loading contract…
BETAThis is a new independent transparency project, not an official government website. The data is sourced from public registers and may contain errors, so always verify against the official source. If you find a problem, please report it here.
A combined autoinjector of pralidoxime chloride and atropine. Estimated Total Value withheld due to commercial sensitivity (s.94(1)(b)). Publication of this information would be likely to prejudice of commercial interests of the incumbent supplier.
No supplier information available.
This procurement was divided into 1 lots, each awarded separately.
| Lot | Value | Status |
|---|---|---|
| Lot 1 Jul 2025 – Jun 2026 | - | planned |